From the Health Economics and Outcomes Research, Astellas Pharma Europe Ltd, Addlestone, United Kingdom.
Department of Gynecology and Obstetrics, Jundiaí School of Medicine, Jundiaí, São Paulo, Brazil.
Menopause. 2023 Dec 1;30(12):1179-1189. doi: 10.1097/GME.0000000000002265. Epub 2023 Oct 19.
This study investigated the prevalence and impact of moderate to severe vasomotor symptoms (VMS), related treatment patterns, and experiences in women.
The primary objective was to assess the prevalence of moderate to severe menopause-related VMS among postmenopausal women aged 40 to 65 years in Brazil, Canada, Mexico, and four Nordic European countries (Denmark, Finland, Norway, and Sweden) using an online survey. Secondary objectives assessed impact of VMS among perimenopausal and postmenopausal women with moderate to severe VMS using the Menopause-Specific Quality of Life questionnaire, Work Productivity and Activity Impairment questionnaire, Patient-Reported Outcomes Measurement Information System sleep disturbances assessment, and questions regarding treatment patterns and attitudes toward symptoms and available treatments.
Among 12,268 postmenopausal women, the prevalence of moderate to severe VMS was about 15.6% and was highest in Brazil (36.2%) and lowest in Nordic Europe (11.6%). Secondary analyses, conducted among 2,176 perimenopausal and postmenopausal women, showed that VMS affected quality of life across all domains measured and impaired work activities by as much as 30%. Greater symptom severity negatively affected sleep. Many women sought medical advice, but most (1,238 [56.9%]) were not receiving treatment for their VMS. The majority (>70%) considered menopause to be a natural part of aging. Those treated with prescription hormone therapy and nonhormone medications reported some safety/efficacy concerns.
Among women from seven countries, moderate to severe menopause-related VMS were widespread, varied by region, and largely impaired quality of life, productivity, and/or sleep.
本研究旨在调查中重度血管舒缩症状（VMS）的流行情况及其对女性的影响、相关治疗模式和治疗体验。
本研究采用在线调查的方式，评估了巴西、加拿大、墨西哥和四个北欧国家（丹麦、芬兰、挪威和瑞典）40 至 65 岁绝经后妇女中与绝经相关的中重度 VMS 的流行率。次要目的是使用绝经特异性生活质量问卷、工作生产力和活动障碍问卷、患者报告的结局测量信息系统睡眠障碍评估、以及关于治疗模式和对症状及现有治疗方法的态度的问题，评估 VMS 对中重度 VMS 围绝经期和绝经后妇女的影响。
在 12268 名绝经后妇女中，中重度 VMS 的流行率约为 15.6%，其中巴西最高（36.2%），北欧最低（11.6%）。在 2176 名围绝经期和绝经后妇女中进行的二次分析显示，VMS 影响了所有测量领域的生活质量，并使工作活动受损高达 30%。症状严重程度的增加会对睡眠产生负面影响。许多女性寻求医疗建议，但大多数（1238 名[56.9%]）未接受 VMS 治疗。大多数女性（>70%）认为绝经是衰老的自然组成部分。接受处方激素治疗和非激素药物治疗的患者报告了一些安全性/疗效方面的担忧。
在来自七个国家的女性中，与绝经相关的中重度 VMS 普遍存在，且因地区而异，对生活质量、生产力和/或睡眠产生了较大影响。
